Table 2 Characteristics of patients with BRONJ who used bisphosphonates.
No | Sex | Age (years) | BRONJ stage | Jaw | Primary disease | Bisphosphonate | Administration route | Medication period (months) | Right parietal bone (SUVmax) | Left parietal bone (SUVmax) | Mean (SUVmax) |
|---|---|---|---|---|---|---|---|---|---|---|---|
15 | F | 90 | 2 | Mandible | OP | Risedronate | IO | 6 | 1.70 | 1.85 | 1.77 |
16 | F | 79 | 3 | Mandible | OP | Risedronate | IO | 24 | 1.51 | 1.39 | 1.45 |
17 | F | 81 | 2 | Mandible | OP | Risedronate | IO | 36 | 0.81 | 0.69 | 0.75 |
18 | F | 79 | 2 | Mandible | OP | Alendronate | IO | 20 | 1.96 | 2.43 | 2.20 |
19 | M | 75 | 3 | Mandible | BM (PC) | Zoledronate | IV | 22 | 1.42 | 1.80 | 1.61 |
20 | F | 67 | 3 | Maxilla | BM (BC) | Zoledronate | IV | 66 | 1.60 | 1.50 | 1.55 |
21 | F | 58 | 2 | Mandible | BM (BC) | Zoledronate | IV | 53 | 1.48 | 1.30 | 1.39 |
22 | F | 76 | 2 | Mandible | BM (BC) | Zoledronate | IV | 46 | 2.25 | 2.49 | 2.37 |
23 | F | 78 | 3 | Maxilla | NPS | Alendronate | IO | 66 | 1.47 | 1.38 | 1.43 |
24 | M | 80 | 2 | Mandible | RA | Alendronate | IO | 48 | 1.14 | 1.10 | 1.12 |
25 | F | 78 | 3 | Mandible | RA | Risedronate | IO | 36 | 1.30 | 1.39 | 1.34 |
26 | F | 63 | 2 | Mandible | RA | Alendronate | IO | 60 | 3.03 | 2.97 | 3.00 |
27 | F | 76 | 2 | Mandible | RA | Risedronate | IO | 60 | 3.77 | 2.89 | 3.33 |
28 | F | 77 | 2 | Mandible | RA | Alendronate | IO | 120 | 1.99 | 1.79 | 1.89 |
29 | F | 66 | 2 | Maxilla | RA | Risedronate | IO | 120 | 4.08 | 3.77 | 3.92 |
Mean | 74.87 | 52.20 | 1.97 | 1.92 | 1.94 | ||||||
SD | 8.11 | 32.90 | 0.95 | 0.83 | 0.88 |
